CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase II clinical trial of self-developed SYH2070 Injection for the treatment of mixed hyperlipidaemia has officially kicked off at the first clinical centre in China. As an siRNA drug targeting ANGPTL3 mRNA, the candidate delivers sustained and stable reduction of triglycerides and low-density lipoprotein cholesterol simultaneously.
NewTimeSpace News: CSPC Pharmaceutical Group Limited released a voluntary announcement dated 7 July 2026. The Phase II clinical trial of SYH2070 Injection independently developed by the Group, indicated for mixed hyperlipidaemia, has been officially launched at the first clinical site in China.
As disclosed in the announcement, SYH2070 is a GalNAc-conjugated small interfering RNA (siRNA) drug targeting angiopoietin-like protein 3 (ANGPTL3) mRNA in hepatocytes. It enables persistent and specific silencing of ANGPTL3 mRNA to suppress the expression of ANGPTL3 protein, thereby achieving long-lasting and steady lowering of both triglycerides and low-density lipoprotein cholesterol. The long dosing interval can greatly improve patient treatment compliance.
The Group obtained the clinical trial approval letter issued by the National Medical Products Administration in September 2025 and has completed the Phase I clinical study. The Phase II trial is designed to evaluate the efficacy, safety, pharmacokinetic profiles and immunogenicity of SYH2070 versus placebo, with a planned enrolment of 240 subjects.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- CSPC PHARMA(01093.HK): Enters Collaboration, Option and Licence Agreement with AstraZeneca for siRNA Drug Development with USD30 Million Upfront Payment
- CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
- CSPC PHARMA(01093.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 859.79 million, YoY decrease of 41.83%
- CSPC PHARMA(01093.HK): Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials for Advanced Solid Tumors
- CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
